Vorasidenib approved to treat patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation gov.uk/government/news/voras…
Servier Receives Positive CHMP Opinion for VORANIGO® (vorasidenib) for the Treatment of Adults and Adolescents with Grade 2 IDH-mutant Diffuse Glioma
servier.mediaroom.com/2025-0…
Our thoughts are with the loved ones of Dr Stu Farrimond, who has sadly passed away.
We are so grateful for everything he did to raise awareness of this cruel disease & fight for better outcomes for those affected.
@theIBTA#BrainTumourResearch#TogetherWeWillFindACure
The GLIORESOLVE project was featured in the 2024/2025 World Edition of the Brain Tumour Magazine, published by the @theIBTA You can read the full publication here issuu.com/ibta-org/docs/ibta… and our article is on Pg 23!
The #EUCancerPlan has been a success for member states, yet so much remains to be done. 👈
Inequalities in reach and accessibility of cancer care persist. The solution: concrete, data-driven insights to drive robust policy action. 📈
The #EuropeanCancerPulse provides vital information that governments, organisations and advocates need to identify weak points and act on them. 💻
Take a look. 🔗 europeancancer.org/pulse
Read our country reports and see for yourself. 📃 europeancancer.org/resources…
📢 Yesterday, SISAQOL-IMI officially launched its final recommendations for standardising patient-reported outcomes in cancer clinical trials! 🎉 A huge step toward better, more reliable data for patient-centered care.
Learn more: sisaqol-imi.org/2025/02/05/s…